📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Aulos Bioscience

1.1 - Company Overview

Aulos Bioscience Logo

Aulos Bioscience

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of cancer immuno-oncology therapeutics, including AU-007, a computationally designed human IgG1 monoclonal antibody that selectively binds to the CD25-binding portion of IL-2 to prevent immune suppression, reduce toxic side effects, and enhance immune activation against solid tumors; plus an AI discovery platform by Biolojic Design using machine learning algorithms to design specific, highly selective functional monoclonal antibodies.

Products and services

  • AU-007: A computationally designed human IgG1 monoclonal antibody that selectively binds the CD25-binding portion of IL-2, preventing immune suppression, reducing toxicity, and enhancing immune activation against solid tumors
  • Artificial Intelligence Discovery Platform: A machine learning-driven Biolojic Design system that architects specific, highly selective functional monoclonal antibodies for therapeutic use
  • Immuno-Oncology Therapeutics: Highly differentiated cancer therapeutics Aulos Bioscience develops to revolutionize patient care in oncology

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Aulos Bioscience

858 Therapeutics Logo

858 Therapeutics

HQ: United States Website
  • Description: Provider of small molecule drug development targeting oncology and immunology.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full 858 Therapeutics company profile →
Medigene Logo

Medigene

HQ: Germany Website
  • Description: Provider of biotechnology solutions for cancer treatment, offering an end-to-end platform for developing TCR-guided therapies—including TCR-T, TCR-T cell engagers, and TCR-natural killer cell therapies—focused on specificity, sensitivity, and safety. Pipeline includes MDG1015 (NY-ESO-1/LAGE-1a, PD1-41BB) and MDG2011 (KRAS G12V, PD1-41BB) for solid tumors, plus 3S TCR technology.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Medigene company profile →
ViraTherapeutics Logo

ViraTherapeutics

HQ: Austria Website
  • Description: Provider of oncolytic virus-based anti-cancer therapeutics, including VSV-GP, a modified Vesicular Stomatitis Virus designed to selectively destroy cancer cells while sparing normal tissues. Offers preclinical safety and efficacy studies for VSV-GP and plans clinical trials to evaluate its therapeutic potential in cancer patients.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ViraTherapeutics company profile →
Kuur Therapeutics Logo

Kuur Therapeutics

HQ: United Kingdom Website
  • Description: Provider of off-the-shelf engineered CAR-NKT cell therapies, combining the natural biology of natural killer T cells with innovative CAR constructs for cancer treatment.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Kuur Therapeutics company profile →
VisionGate Logo

VisionGate

HQ: United States Website
  • Description: Provider of an automated 3D cell imaging platform for early cancer detection and prevention.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full VisionGate company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Aulos Bioscience

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Aulos Bioscience

2.2 - Growth funds investing in similar companies to Aulos Bioscience

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Aulos Bioscience

4.2 - Public trading comparable groups for Aulos Bioscience

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Aulos Bioscience

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Aulos Bioscience

What does Aulos Bioscience do?

Aulos Bioscience is a provider of cancer immuno-oncology therapeutics, including AU-007, a computationally designed human IgG1 monoclonal antibody that selectively binds to the CD25-binding portion of IL-2 to prevent immune suppression, reduce toxic side effects, and enhance immune activation against solid tumors; plus an AI discovery platform by Biolojic Design using machine learning algorithms to design specific, highly selective functional monoclonal antibodies.

Who are Aulos Bioscience's competitors?

Aulos Bioscience's competitors and similar companies include 858 Therapeutics, Medigene, ViraTherapeutics, Kuur Therapeutics, and VisionGate.

Where is Aulos Bioscience headquartered?

Aulos Bioscience is headquartered in United States.

How many employees does Aulos Bioscience have?

Aulos Bioscience has 1,000 employees 🔒.

When was Aulos Bioscience founded?

Aulos Bioscience was founded in 2010 🔒.

What sector and industry vertical is Aulos Bioscience in?

Aulos Bioscience is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Aulos Bioscience

Who are the top strategic acquirers in Aulos Bioscience's sector and industry

Top strategic M&A buyers and acquirers in Aulos Bioscience's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Aulos Bioscience?

Top strategic M&A buyers groups and sectors for Aulos Bioscience include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Aulos Bioscience's sector and industry vertical

Which are the top PE firms investing in Aulos Bioscience's sector and industry vertical?

Top PE firms investing in Aulos Bioscience's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Aulos Bioscience's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Aulos Bioscience's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Aulos Bioscience's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Aulos Bioscience include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Aulos Bioscience's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Aulos Bioscience?

The key public trading comparables and valuation benchmarks for Aulos Bioscience include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Aulos Bioscience for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Aulos Bioscience with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Aulos Bioscience's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Aulos Bioscience with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Aulos Bioscience's' sector and industry vertical?

Access recent funding rounds and capital raises in Aulos Bioscience's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Aulos Bioscience